EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

Dual PD ‐1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers

Cristina P Rodriguez iD, Qian Vicky Wu, Kevin Ng, Jenna Voutsinas, Jonathan R Fromm, Ariana Dumenigo-Jimenez, Renato G Martins, Keith D Eaton, Rafael Santana-Davila, Christina Baik, Sylvia M Lee, Diane Tseng und 7 weitere

Head & Neck · 2025

DOI: 10.1002/hed.28169 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Head & Neck, 2025. Verfasst von Cristina P Rodriguez und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Nivolumab, Immune Checkpoint Inhibitors, Ipilimumab. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No standard systemic therapy exists for recurrent/metastatic salivary gland cancer (R/M SGC). We explored the safety and activity of nivolumab and ipilimumab with palliative hypofractionated radiation (XRT) in this population.

Methods

This Phase I/II Trial enrolled R/M SGCs with evidence of progression, ECOG 0–1, no prior anti‐PD‐1 or CTLA4 therapy, measurable disease excluding the XRT site. Nivolumab 3 mg/kg iv Q2 weeks × 12 doses followed by 480 mg iv Q4 weeks × 8 doses and ipilimumab 1 mg/kg iv Q6 weeks × 4 doses was given. Twenty four gray XRT was given over three fractions, 2 weeks after the first dose of nivolumab. The primary endpoint was safety; secondary endpoints included RECIST 1.1 response (non‐radiated lesions), progression free, and overall survival.

Results

Between April 2019 and May 2022, 20 pts. were enrolled, the median age was 58 (range 27–77 years), 10 (50%) were male, and 12 (60%) had ECOG 0. Five (20%) Grade 3 AEs were observed in three pts.; no Grade 4 or 5 toxicities were observed. Among 19 response‐evaluable patients, RECIST 1.1 PRs were observed in 4 (21%), in 2 pts. with salivary duct, 1 acinic cell, and 1 adenoid cystic, SD in 6 (31.5%) and PD in 9 (47.5%). With a median follow‐up of 16 months, median OS was 25 months (95% CI: [18.7, 31]) and median PFS was 7.3 months (95% CI [2.5, 18.7]).

Conclusion

Nivolumab/ipilimumab and palliative XRT result in low rates of severe toxicities and modest response rates for SGC; further work is necessary to explore predictors for response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salivary Gland NeoplasmsNivolumabImmune Checkpoint InhibitorsIpilimumabHumansMaleMiddle AgedFemaleAgedAdultRadiation Dose HypofractionationProgrammed Cell Death 1 ReceptorCTLA-4 Antigen

Stichwörter der Autor:innen

clinical trialimmunotherapymetastaticradiationsalivary gland cancer

Substanzen

NivolumabImmune Checkpoint InhibitorsIpilimumabProgrammed Cell Death 1 ReceptorCTLA-4 Antigen

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Otolaryngology Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
  • Department of Radiation Oncology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Cristina P Rodriguez

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Rodriguez, C. P., Wu, Q. V., Ng, K., Voutsinas, J., Fromm, J. R., Dumenigo-Jimenez, A., Martins, R. G., Eaton, K. D., Santana-Davila, R., Baik, C., Lee, S. M., Tseng, D., Futran, N., Barber, B., Marchiano, E., Laramore, G., Lo, S. S., Liao, J. J., & Parvathaneni, U. (2025). Dual PD ‐1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers. Head & Neck. https://doi.org/10.1002/hed.28169

Vancouver

Rodriguez CP, Wu QV, Ng K, Voutsinas J, Fromm JR, Dumenigo-Jimenez A, et al. Dual PD ‐1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers. Head & Neck. 2025. doi:10.1002/hed.28169

BibTeX
@article{Rodriguez2025,
  author = {Rodriguez, Cristina P and Wu, Qian Vicky and Ng, Kevin and Voutsinas, Jenna and Fromm, Jonathan R and Dumenigo-Jimenez, Ariana and Martins, Renato G and Eaton, Keith D and Santana-Davila, Rafael and Baik, Christina and Lee, Sylvia M and Tseng, Diane and Futran, Neal and Barber, Brittany and Marchiano, Emily and Laramore, George and Lo, Simon S and Liao, Jay J and Parvathaneni, Upendra},
  title = {Dual PD ‐1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.28169}
}
Kostenlos starten →